ACMT urges clinical oversight for concentrated 7-OH products

Why it matters

The medical toxicology group’s statement gives clinicians and policymakers a current, specialty-society view of concentrated 7-OH products. It distinguishes those products from traditional leaf preparations while calling for more research.

The big picture

7-OH is present in trace amounts in kratom leaf and can also result from mitragynine metabolism. ACMT says concentrated 7-OH products became broadly available in U.S. retail and online markets in the late 2010s, and evidence on human safety, dosing, and pharmacokinetics remains incomplete.

Key findings

• ACMT says animal studies show 7-OH and related compounds can produce opioid-like effects.
• The statement cites clinical reports of intoxication, respiratory depression, dependence, withdrawal, overdose, and death associated with 7-OH.
• It reports that naloxone reversed 7-OH-associated respiratory depression in animal work and human case reports.
• The group says buprenorphine has been used to treat kratom- and 7-OH-related withdrawal.
• ACMT says there are no proven therapeutic benefits for 7-OH and no safe dose can be recommended.

What they say

“Additional clinical research is needed to better define their pharmacology, safety profile, and potential therapeutic applications.”

Bottom line

**ACMT recommends that use of 7-OH occur only in appropriately overseen clinical research while its safety and therapeutic profile are clarified.**